Nishitha R Pillai1, Bridget M Stroup2, Anna Poliner2, Linda Rossetti1, Brandy Rawls3, Brian J Shayota1, Claudia Soler-Alfonso1, Hari Priya Tunuguntala4, John Goss5, William Craigen1, Fernando Scaglia6, V Reid Sutton1, Ryan Wallace Himes7, Lindsay C Burrage8. 1. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA; Texas Children's Hospital, Houston, TX, USA. 2. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA. 3. Texas Children's Hospital, Houston, TX, USA. 4. Texas Children's Hospital, Houston, TX, USA; Section of Pediatric Cardiology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. 5. Texas Children's Hospital, Houston, TX, USA; Section of Gastroenterology, Hepatology and Nutrition, Baylor College of Medicine, Houston, TX, USA. 6. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA; Texas Children's Hospital, Houston, TX, USA; Joint BCM-CUHK Center of Medical Genetics, Prince of Wales Hospital, Hong Kong Special Administrative Region. 7. Texas Children's Hospital, Houston, TX, USA; Section of Gastroenterology, Hepatology and Nutrition, Baylor College of Medicine, Houston, TX, USA. Electronic address: ryan.himes@ochsner.org. 8. Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA; Texas Children's Hospital, Houston, TX, USA. Electronic address: burrage@bcm.edu.
Abstract
BACKGROUND: Organic acidemias, especially propionic acidemia (PA) and methylmalonic acidemia (MMA), may manifest clinically within the first few hours to days of life. The classic presentation in the newborn period includes metabolic acidosis, hyperlactatemia, and hyperammonemia that is precipitated by unrestricted protein intake. Implementation of newborn screening to diagnose and initiate early treatment has facilitated a reduction in neonatal mortality and improved survival. Despite early diagnosis and appropriate management, these individuals are prone to have recurrent episodes of metabolic acidosis and hyperammonemia resulting in frequent hospitalizations. Liver transplantation (LT) has been proposed as a treatment modality to reduce metabolic decompensations which are not controlled by medical management. Published reports on the outcome of LT show heterogeneous results regarding clinical and biochemical features in the post transplantation period. As a result, we evaluated the outcomes of LT in our institution and compared it to the previously published data. STUDY DESIGN/ METHODS: We performed a retrospective chart review of nine individuals with PA or MMA who underwent LT and two individuals with MMA who underwent LT and kidney transplantation (KT). Data including number of hospitalizations, laboratory measures, cardiac and neurological outcomes, dietary protein intake, and growth parameters were collected. RESULTS: The median age of transplantation for subjects with MMA was 7.2 years with a median follow up of 4.3 years. The median age of transplantation for subjects with PA was 1.9 years with a median follow up of 5.4 years. The survival rate at 1 year and 5 years post-LT was 100%. Most of our subjects did not have any episodes of hyperammonemia or pancreatitis post-LT. There was significant reduction in plasma glycine post-LT. One subject developed mild elevation in ammonia post-LT on an unrestricted protein diet, suggesting that protein restriction may be indicated even after LT. CONCLUSION: In a large single center study of LT in MMA and PA, we show that LT may reduce the incidence of metabolic decompensation. Moreover, our data suggest that LT may be associated with reduced number of hospitalizations and improved linear growth in individuals with PA and MMA.
BACKGROUND:Organic acidemias, especially propionic acidemia (PA) and methylmalonic acidemia (MMA), may manifest clinically within the first few hours to days of life. The classic presentation in the newborn period includes metabolic acidosis, hyperlactatemia, and hyperammonemia that is precipitated by unrestricted protein intake. Implementation of newborn screening to diagnose and initiate early treatment has facilitated a reduction in neonatal mortality and improved survival. Despite early diagnosis and appropriate management, these individuals are prone to have recurrent episodes of metabolic acidosis and hyperammonemia resulting in frequent hospitalizations. Liver transplantation (LT) has been proposed as a treatment modality to reduce metabolic decompensations which are not controlled by medical management. Published reports on the outcome of LT show heterogeneous results regarding clinical and biochemical features in the post transplantation period. As a result, we evaluated the outcomes of LT in our institution and compared it to the previously published data. STUDY DESIGN/ METHODS: We performed a retrospective chart review of nine individuals with PA or MMA who underwent LT and two individuals with MMA who underwent LT and kidney transplantation (KT). Data including number of hospitalizations, laboratory measures, cardiac and neurological outcomes, dietary protein intake, and growth parameters were collected. RESULTS: The median age of transplantation for subjects with MMA was 7.2 years with a median follow up of 4.3 years. The median age of transplantation for subjects with PA was 1.9 years with a median follow up of 5.4 years. The survival rate at 1 year and 5 years post-LT was 100%. Most of our subjects did not have any episodes of hyperammonemia or pancreatitis post-LT. There was significant reduction in plasma glycine post-LT. One subject developed mild elevation in ammonia post-LT on an unrestricted protein diet, suggesting that protein restriction may be indicated even after LT. CONCLUSION: In a large single center study of LT in MMA and PA, we show that LT may reduce the incidence of metabolic decompensation. Moreover, our data suggest that LT may be associated with reduced number of hospitalizations and improved linear growth in individuals with PA and MMA.
Authors: Paige Kaplan; Can Ficicioglu; Alice T Mazur; Michael J Palmieri; Gerard T Berry Journal: Mol Genet Metab Date: 2006-06-05 Impact factor: 4.797
Authors: Blake A Hamby; Daniel E Ramirez; George E Loss; Hernan A Bazan; Taylor A Smith; Edward Bluth; W Charles Sternbergh Journal: J Vasc Surg Date: 2013-01-18 Impact factor: 4.268
Authors: T Yorifuji; M Kawai; M Mamada; K Kurokawa; H Egawa; Y Shigematsu; Y Kohno; K Tanaka; T Nakahata Journal: J Inherit Metab Dis Date: 2004 Impact factor: 4.982
Authors: Randy J Chandler; Giovanni Di Pasquale; Jennifer L Sloan; Samantha McCoy; Brandon T Hubbard; Tina M Kilts; Irini Manoli; John A Chiorini; Charles P Venditti Journal: Mol Ther Methods Clin Dev Date: 2022-09-06 Impact factor: 5.849
Authors: Oleg A Shchelochkov; Irini Manoli; Paul Juneau; Jennifer L Sloan; Susan Ferry; Jennifer Myles; Megan Schoenfeld; Alexandra Pass; Samantha McCoy; Carol Van Ryzin; Olivia Wenger; Mark Levin; Wadih Zein; Laryssa Huryn; Joseph Snow; Colby Chlebowski; Audrey Thurm; Jeffrey B Kopp; Kong Y Chen; Charles P Venditti Journal: Genet Med Date: 2021-05-18 Impact factor: 8.822
Authors: Randy J Chandler; Leah E Venturoni; Jing Liao; Brandon T Hubbard; Jessica L Schneller; Victoria Hoffmann; Susana Gordo; Shengwen Zang; Chih-Wei Ko; Nelson Chau; Kyle Chiang; Mark A Kay; Adi Barzel; Charles P Venditti Journal: Hepatology Date: 2021-05-21 Impact factor: 17.298